These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 2926879

  • 1. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
    Bretton PR, Herr HW, Whitmore WF, Badalament RA, Kimmel M, Provet J, Oettgen HF, Melamed MR, Fair WR.
    J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
    [Abstract] [Full Text] [Related]

  • 2. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
    Hillyard RW, Ladaga L, Schellhammer PF.
    J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH, Davis J, Schellhammer P.
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [Abstract] [Full Text] [Related]

  • 4. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J, Xavier B, Laguna P, Montlleó M, Vicente J.
    Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
    [Abstract] [Full Text] [Related]

  • 5. Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder.
    Schellhammer PF, Ladaga LE, Moriarty RP.
    J Urol; 1995 Jan; 153(1):53-6. PubMed ID: 7966790
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG.
    Orihuela E, Herr HW, Whitmore WF.
    Urology; 1989 Nov; 34(5):231-7. PubMed ID: 2815442
    [Abstract] [Full Text] [Related]

  • 10. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG, Neulander E, Murphy WM, Wajsman Z.
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [Abstract] [Full Text] [Related]

  • 11. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J, Schatteman P, Huguet Pérez J, Segarra Tomás J, Rosales Bordes A, Algaba F, Villavicencio Mavrich H.
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [Abstract] [Full Text] [Related]

  • 12. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 13. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 14. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
    Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G.
    Urologia; 2010 Sep; 77 Suppl 17():72-7. PubMed ID: 21308679
    [Abstract] [Full Text] [Related]

  • 15. [Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Wakabayashi Y, Okada Y, Mukumoto K, Hamaguchi A, Konishi T, Tomoyoshi T.
    Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2146-51. PubMed ID: 8309122
    [Abstract] [Full Text] [Related]

  • 16. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR.
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [Abstract] [Full Text] [Related]

  • 17. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [Abstract] [Full Text] [Related]

  • 18. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.
    Bassi P.
    Surg Oncol; 2002 Jun; 11(1-2):77-83. PubMed ID: 12031870
    [Abstract] [Full Text] [Related]

  • 19. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
    Loertzer H, Brake M, Horsch R, Keller H.
    Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
    [Abstract] [Full Text] [Related]

  • 20. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL.
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.